CAPTRUST Financial Advisors’s Idexx Laboratories IDXX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $18.4M | Buy |
35,025
+2,897
| +9% | +$1.62M | 0.03% | 416 |
|
|
2026
Q1 | $18.1M | Buy |
32,128
+2,704
| +9% | +$1.73M | 0.03% | 392 |
|
|
2025
Q4 | $19.9M | Buy |
29,424
+20,361
| +225% | +$13.9M | 0.04% | 333 |
|
|
2025
Q3 | $5.79M | Sell |
9,063
-1,071
| -11% | -$650K | 0.01% | 595 |
|
|
2025
Q2 | $5.44M | Buy |
10,134
+563
| +6% | +$269K | 0.01% | 602 |
|
|
2025
Q1 | $4.02M | Buy |
9,571
+3,746
| +64% | +$1.63M | 0.01% | 645 |
|
|
2024
Q4 | $2.41M | Buy |
5,825
+1,078
| +23% | +$473K | 0.01% | 806 |
|
|
2024
Q3 | $2.4M | Sell |
4,747
-651
| -12% | -$316K | 0.01% | 790 |
|
|
2024
Q2 | $2.63M | Buy |
5,398
+41
| +0.8% | +$20.6K | 0.01% | 694 |
|
|
2024
Q1 | $2.89M | Sell |
5,357
-3,670
| -41% | -$2.01M | 0.01% | 667 |
|
|
2023
Q4 | $5.01M | Sell |
9,027
-158
| -2% | -$74.2K | 0.02% | 559 |
|
|
2023
Q3 | $4.02M | Buy |
9,185
+2,952
| +47% | +$1.47M | 0.02% | 594 |
|
|
2023
Q2 | $3.13M | Buy |
6,233
+278
| +5% | +$133K | 0.01% | 664 |
|
|
2023
Q1 | $2.98M | Sell |
5,955
-219
| -4% | -$105K | 0.01% | 619 |
|
|
2022
Q4 | $2.52M | Sell |
6,174
-130
| -2% | -$50.5K | 0.01% | 638 |
|
|
2022
Q3 | $2.05M | Buy |
6,304
+1,671
| +36% | +$614K | 0.01% | 661 |
|
|
2022
Q2 | $1.63M | Buy |
4,633
+1,272
| +38% | +$519K | 0.01% | 659 |
|
|
2022
Q1 | $1.84M | Sell |
3,361
-999
| -23% | -$526K | 0.01% | 621 |
|
|
2021
Q4 | $2.87M | Buy |
4,360
+425
| +11% | +$267K | 0.02% | 481 |
|
|
2021
Q3 | $2.45M | Buy |
3,935
+427
| +12% | +$287K | 0.02% | 476 |
|
|
2021
Q2 | $2.21M | Sell |
3,508
-1,230
| -26% | -$679K | 0.02% | 471 |
|
|
2021
Q1 | $2.32M | Buy |
4,738
+1,502
| +46% | +$753K | 0.03% | 432 |
|
|
2020
Q4 | $1.62M | Buy |
3,236
+171
| +6% | +$76.5K | 0.02% | 459 |
|
|
2020
Q3 | $1.21M | Sell |
3,065
-137
| -4% | -$50.7K | 0.02% | 451 |
|
|
2020
Q2 | $1.07M | Buy |
3,202
+985
| +44% | +$285K | 0.02% | 484 |
|
|
2020
Q1 | $511K | Buy |
2,217
+353
| +19% | +$92.1K | 0.01% | 587 |
|
|
2019
Q4 | $494K | Buy |
1,864
+1,737
| +1,368% | +$458K | 0.01% | 690 |
|
|
2019
Q3 | $35K | Sell |
127
-24
| -16% | -$6.68K | ﹤0.01% | 1112 |
|
|
2019
Q2 | $42K | Buy |
151
+37
| +32% | +$9.12K | ﹤0.01% | 1034 |
|
|
2019
Q1 | $25K | Buy |
+114
| New | +$23.5K | ﹤0.01% | 1105 |
|
|
2018
Q3 | – | Sell |
-3
| Closed | -$1K | – | 1633 |
|
|
2018
Q2 | $1K | Buy |
+3
| New | +$618 | ﹤0.01% | 1451 |
|
Other funds holding IDXX
CAPTRUST Financial Advisors's IDXX Position: Q2 2026 in Review
CAPTRUST Financial Advisors increased its Idexx Laboratories (IDXX) stake by 9% in Q2 2026, buying an estimated $1.62M and bringing the position to 35,025 shares worth $18.4M. The position accounts for 0.03% of the portfolio, ranked #416.
CAPTRUST Financial Advisors first reported a position in IDXX in Q2 2018 and has held it in 31 quarters since. The position peaked at $19.9M in Q4 2025. 1,305 funds tracked by Wall St. Rank hold IDXX as of Q2 2026.
- CAPTRUST Financial Advisors held 35,025 shares of Idexx Laboratories worth $18.4M as of Q2 2026.
- CAPTRUST Financial Advisors bought 2,897 Idexx Laboratories shares in Q2 2026, an estimated $1.62M.
- Idexx Laboratories made up 0.03% of CAPTRUST Financial Advisors's portfolio in Q2 2026, its #416 holding.
- CAPTRUST Financial Advisors first reported a position in Idexx Laboratories in Q2 2018 and has held it in 31 quarters since.
- CAPTRUST Financial Advisors's Idexx Laboratories position peaked at $19.9M in Q4 2025.
- 1,305 funds tracked by Wall St. Rank held Idexx Laboratories as of Q2 2026.
Based on CAPTRUST Financial Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.